Top Markets
Coin of the day
Icosavax, Inc. Icosavax, Inc.

Icosavax, Inc.

ICVX
Rang in Aktien #25854
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing... Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Aktienkurs
$15.31
Zuletzt synchronisiert: 2024-02-29
Marktkapitalisierung
$45.70M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Icosavax, Inc. (ICVX)

Kategorie

Kursverlauf für Icosavax, Inc. (ICVX)
Höchster Schlusskurs: $15.31 am 2024-02-01

Niedrigster Schlusskurs: $29.91 am 2021-07-01
Kursverlauf der Aktie von Icosavax, Inc. von 2021 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2024 10.83%
2023 104.14%
2022 -70.48%
2021 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$539.14 35.65%
US
$1.04K 56.21%
NL
$119.69 -17.56%
AU
$761.87 8.65%
CH
$130.43 397.46%
US